Bexagliflozin vs Olorigliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Bexagliflozin · Brenzavvy

Marketed by Theracos and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT02558296 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison at week 24 was statistically significant in favor of bexagliflozin. HbA1c is an approvable primary endpoint in type 2 diabetes, so the design and the result support strong evidence.

Next expected readout: March 2029 · NCT07547878 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058) (met)

Result source: NCT02769481

Olorigliflozin

Marketed by Sunshine Lake Pharma

Phase 1 in Type 2 Diabetessmall molecule
Weak signal

NCT05427682 · Phase 1 · completed

A non-randomized, open-label, parallel-group pharmacokinetic study of rongliflozin in 32 participants with normal or impaired liver function. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBexagliflozinOlorigliflozin
HbA1c, change-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
—Not reported
Body weight, change (kg)-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
—Not reported
HbA1c below 7%—Not reported—Not reported
Fasting plasma glucose, change-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Bexagliflozin
-0.8% vs -0.4%−0.5 vs placebo20 mg · wk 24 · n 1046NCT02558296
23 other results
  • -1.1% vs -0.6% 20 mg · wk 24 · n 142 · Phase 3 · primary NCT03259789
  • -0.5% vs -0.1% 20 mg · wk 24 · n 138 · Phase 3 · primary NCT02715258
  • -0.6% vs -0.3% 20 mg · wk 24 · n 157 · Phase 3 · primary NCT02836873
  • -0.7% vs -0.7% wk 60 · n 193 · Phase 3 · primary NCT02769481
  • -0.7% vs -0.8% wk 24 · n 180 · Phase 3 · primary NCT03115112
  • -1.1% vs -0.6% 20 mg · wk 24 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs -0.4% 20 mg · wk 24 · n 86 · Phase 3 · secondary NCT02836873
  • -0.6% vs -0.2% 20 mg · wk 24 · n 71 · Phase 3 · secondary NCT02836873
  • -1% vs -0.5% 20 mg · wk 18 · n 158 · Phase 3 · secondary NCT03259789
  • -1.0% vs -0.3% 20 mg · wk 12 · n 158 · Phase 3 · secondary NCT03259789
  • -0.7% vs -0.2% 20 mg · wk 6 · n 158 · Phase 3 · secondary NCT03259789
  • -0.6% vs 0.2% 20 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 68 · Phase 2 · primary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 65 · Phase 2 · primary NCT02390050
  • -0.6% vs 0.2% 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.2% 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -0.4% vs 0.1% 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.2% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.3% vs 0.1% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.1% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Olorigliflozin
—Not reported

Body weight, change (kg)

Bexagliflozin
-3.0 vs -0.4−2.6 vs placebo20 mg · wk 48 · n 922NCT02558296
14 other results
  • -3.6 vs -1.1 20 mg · wk 24 · n 119 · Phase 3 · secondary NCT03259789
  • -1.9 vs -1.1 20 mg · wk 24 · n 128 · Phase 3 · secondary NCT02715258
  • -2.3 vs -0.6 20 mg · wk 24 · n 122 · Phase 3 · secondary NCT02836873
  • -3.7 vs 0.6 wk 60 · n 182 · Phase 3 · secondary NCT02769481
  • -3.4 vs -0.8 wk 24 · n 158 · Phase 3 · secondary NCT03115112
  • -1.9 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.5 vs 0.0 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.7 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.4 vs 0.0 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.6 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -1 vs 0.0 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.7 vs 0 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Olorigliflozin
—Not reported

HbA1c below 7%

Bexagliflozin
—Not reported
Olorigliflozin
—Not reported

Fasting plasma glucose, change

Bexagliflozin
-2.5 vs -1.2−1.3 vs placebo20 mg · wk 24 · n 142NCT03259789
10 other results
  • -1.8 vs -1.4 wk 24 · n 180 · Phase 3 · secondary NCT03115112
  • -1.2 vs -0.1 20 mg · wk 12 · n 75 · Phase 2 · secondary NCT02390050
  • -1.0 vs 0.1 20 mg · wk 6 · n 75 · Phase 2 · secondary NCT02390050
  • -1.1 vs -0.1 20 mg · wk 2 · n 75 · Phase 2 · secondary NCT02390050
  • -1.2 vs -0.1 10 mg · wk 12 · n 72 · Phase 2 · secondary NCT02390050
  • -1.1 vs 0.1 10 mg · wk 6 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 10 mg · wk 2 · n 72 · Phase 2 · secondary NCT02390050
  • -1.0 vs -0.1 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT02390050
  • -0.8 vs 0.1 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT02390050
  • -0.6 vs -0.1 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT02390050
Olorigliflozin
—Not reported

3-point MACE (% with event)

Bexagliflozin
—Not reported
Olorigliflozin
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Olorigliflozin: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bexagliflozin: 4 of 4 rows · Olorigliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBexagliflozin
Dropout rate
3.9%20 mga
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
15.5%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.8%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
11.4%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.3%
NCT03115112 · Phase 3
3.2%20 mg
NCT02836873 · Phase 3
9.2%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
6.9%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0.8%20 mga
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
1.4%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
—20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.6%
NCT03115112 · Phase 3
0.6%20 mg
NCT02836873 · Phase 3
—20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
—Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
—Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
—Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
—Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
Serious AEs
33%20 mga
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.9%20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.7%20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.7%
NCT03115112 · Phase 3
7%20 mg
NCT02836873 · Phase 3
2.6%20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
4.2%10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
0%Study 1: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 1: Bexagliflozin and Probene
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 2: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 2: Bexagliflozin and Rrifamp
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Study 3: Bexagliflozin Alone
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
0%Study 3: Bexagliflozin and Verapam
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
0%Bexagliflozin Tablet Dosed in Fast
NCT02820298 · Phase 1 · registry result, not featured evidence
0%Bexagliflozin Tablet Dosed in Fed
NCT02820298 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
20 mga
hypoglycaemia 42% (placebo 43.4%)
urinary tract infection 11.3% (placebo 10.6%)
upper respiratory tract infection 9.9% (placebo 9.3%)
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 16 more results
hypoglycemia 16.9%
nasopharyngitis 13.6%
urinary tract infection 11.7%
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20 mg
nasopharyngitis 5.7% (placebo 8.2%)
polydipsia 3.2% (placebo 2.5%)
polyuria 3.2% (placebo 3.8%)
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
20 mg
polyuria 7.2% (placebo 2.9%)
urinary tract infection 5.1% (placebo 2.9%)
abdominal pain 3.6% (placebo 7.2%)
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 7.9%
urinary tract infection 3.7%
hypoglycemia 3.1%
NCT03115112 · Phase 3
20 mg
hypoglycaemia 25.5% (placebo 25.8%)
polyuria 7.6% (placebo 4.5%)
nasopharyngitis 7% (placebo 8.4%)
NCT02836873 · Phase 3
20 mg
hypoglycemia 5.3% (placebo 1.4%)
dysuria 3.9% (placebo 1.4%)
nasopharyngitis 3.9% (placebo 4.2%)
NCT02390050 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 5.6% (placebo 4.2%)
pharyngitis 4.2% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT02390050 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 6.9% (placebo 4.2%)
diarrhea 2.8% (placebo 2.8%)
dizziness 2.8% (placebo 1.4%)
NCT02390050 · Phase 2 · registry result, not featured evidence
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 6.3%
gastrointestinal sounds abnormal 6.3%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
laceration 6.3%
presyncope 6.3%
diarrhea 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · monotherapy
diarrhea 0%
gastrointestinal sounds abnormal 0%
laceration 0%
NCT03296800 · Phase 1 · registry result, not featured evidence · combination
dizziness 4.2%
headache 4.2%
nasal congestion 4.2%
NCT02820298 · Phase 1 · registry result, not featured evidence
chest discomfort 4.3%
dizziness 4.3%
headache 4.3%
NCT02820298 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bexagliflozin

HbA1c -0.85% (n=1046) vs -0.37% (n=531) placebo @ 24wk20 mg
absolute change · percentage points
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
-1.09% (n=142) vs -0.56% (n=145) placebo @ 24wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
-0.72% (n=158) vs -0.16% (n=159) placebo @ 6wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
-0.97% (n=158) vs -0.31% (n=159) placebo @ 12wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
-1% (n=158) vs -0.51% (n=159) placebo @ 18wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
-1.09% (n=158) vs -0.56% (n=159) placebo @ 24wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
-0.51% (n=138) vs -0.1% (n=69) placebo @ 24wk20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.59% (n=157) vs -0.31% (n=155) placebo @ 24wk20 mg
NCT02836873 · Phase 3
-0.63% (n=86) vs -0.44% (n=80) placebo @ 24wk20 mg
NCT02836873 · Phase 3
-0.57% (n=71) vs -0.2% (n=75) placebo @ 24wk20 mg
NCT02836873 · Phase 3
-0.56% (n=68) vs 0.24% (n=64) placebo @ 12wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.13% (n=75) vs 0% (n=72) placebo @ 2wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.4% (n=75) vs 0.13% (n=72) placebo @ 6wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.56% (n=75) vs 0.24% (n=72) placebo @ 12wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.44% (n=68) vs 0.24% (n=64) placebo @ 12wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.13% (n=72) vs 0% (n=72) placebo @ 2wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.36% (n=72) vs 0.13% (n=72) placebo @ 6wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.44% (n=72) vs 0.24% (n=72) placebo @ 12wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.31% (n=65) vs 0.24% (n=64) placebo @ 12wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.09% (n=71) vs 0% (n=72) placebo @ 2wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.32% (n=71) vs 0.13% (n=72) placebo @ 6wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.31% (n=71) vs 0.24% (n=72) placebo @ 12wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.7% (n=193) vs -0.66% (n=191) Glimepiride @ 60wk
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.74% (n=180) vs -0.82% (n=190) Sitagliptin @ 24wk
NCT03115112 · Phase 3
Weight -3.03 vs -0.38 placebo kg @ 48wk20 mg
absolute change · kg
NCT02558296 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 14 more results
-3.6 vs -1.09 placebo kg @ 24wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
-1.85 vs -1.06 placebo kg @ 24wk20 mg
NCT02715258 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-2.31 vs -0.55 placebo kg @ 24wk20 mg
NCT02836873 · Phase 3
-0.99 vs 0 placebo kg @ 2wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.49 vs 0.02 placebo kg @ 6wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.89 vs -0.14 placebo kg @ 12wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.76 vs 0 placebo kg @ 2wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.42 vs 0.02 placebo kg @ 6wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.72 vs -0.14 placebo kg @ 12wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.74 vs 0 placebo kg @ 2wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1 vs 0.02 placebo kg @ 6wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.58 vs -0.14 placebo kg @ 12wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-3.71 vs 0.59 Glimepiride kg @ 60wk
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-3.35 vs -0.81 Sitagliptin kg @ 24wk
NCT03115112 · Phase 3
Seated SBP -13.48 vs -6.95 Glimepiride mmHg @ 60wk
absolute change · mmHg
NCT02769481 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -2.51 vs -1.16 placebo mmol/L @ 24wk20 mg
absolute change · mmol/L
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
show 10 more results
-1.11 vs -0.07 placebo mmol/L @ 2wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.99 vs 0.11 placebo mmol/L @ 6wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.18 vs -0.11 placebo mmol/L @ 12wk20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.97 vs -0.07 placebo mmol/L @ 2wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.06 vs 0.11 placebo mmol/L @ 6wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.16 vs -0.11 placebo mmol/L @ 12wk10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.55 vs -0.07 placebo mmol/L @ 2wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.82 vs 0.11 placebo mmol/L @ 6wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-0.96 vs -0.11 placebo mmol/L @ 12wk5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence
-1.82 vs -1.45 Sitagliptin mmol/L @ 24wk
NCT03115112 · Phase 3
SBP -5.03 vs 2.04 placebo mmHg @ 24wk20 mg
absolute change · mmHg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
-10.14 vs -7.51 placebo mmHg @ 24wk20 mg
NCT02836873 · Phase 3
-4.23 vs -1.9 Sitagliptin mmHg @ 24wk
NCT03115112 · Phase 3
HbA1c 7.0 or Less 0.14% (n=158) vs 0.03% (n=159) placebo @ 6wk20 mg
event count · % of participants
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
show 6 more results
0.26% (n=158) vs 0.06% (n=159) placebo @ 12wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.26% (n=158) vs 0.1% (n=159) placebo @ 18wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
0.38% (n=158) vs 0.1% (n=159) placebo @ 24wk20 mg
NCT03259789 · Phase 3 · Type 2 Diabetes · phase 3
36% (n=75) vs 15.3% (n=72) placebo @ 12wk*20 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
22.2% (n=72) vs 15.3% (n=72) placebo @ 12wk*10 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
21.1% (n=71) vs 15.3% (n=72) placebo @ 12wk*5 mg
NCT02390050 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · Olorigliflozin's landscape